Skip to main content

MINI REVIEW article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1397186
This article is part of the Research Topic Transplantation and Cellular Therapy in Lymphomas and Plasma Cell Disorders View all 13 articles

On the road to a durable remission by CAR or by conventional means: Re-examining the role for hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy

Provisionally accepted
Tamara K. Moyo Tamara K. Moyo 1*Rakhee Vaidya Rakhee Vaidya 2
  • 1 Levine Cancer Institute, Atrium Health Carolinas Medical Center (CMC), North Carolina, United States
  • 2 Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

The final, formatted version of the article will be published soon.

    Historically, salvage chemoimmunotherapy with consolidative autologous hematopoietic stem cell transplantation (ASCT) was the only potentially curative therapeutic option for patients with relapsed/refractory large B-cell lymphoma (LBCL). Treatment options were few and outcomes poor for patients whose lymphoma failed to respond to salvage chemotherapy/ASCT and for patients not eligible for ASCT. The approval of chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory LBCL revolutionized the treatment landscape with unprecedented response rates and durability of responses. As a result, earlier intervention with CAR T-cell therapy has been explored, and the enthusiasm for CAR T-cell therapy has overshadowed ASCT. In this article, we will review the data available for ASCT and CAR T-cell therapy in relapsed LBCL and will examine the role for ASCT in relapsed/refractory LBCL in the era of CAR T-cell therapy.

    Keywords: relapsed large B-cell lymphoma (LBCL), CAR T-cell therapy, autologous stem cell transplant (ASCT), tisagenlecleucel, Axicabtagene ciloleucel, Lisocabtagene maraleucel

    Received: 07 Mar 2024; Accepted: 22 Jul 2024.

    Copyright: © 2024 Moyo and Vaidya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tamara K. Moyo, Levine Cancer Institute, Atrium Health Carolinas Medical Center (CMC), North Carolina, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.